Welcome to our dedicated page for INSMED SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed reported sharply higher revenue but remained unprofitable in the quarter ended March 31, 2026. Product revenues, net rose to $305.964 million from $92.823 million a year earlier, driven by the US launch of BRINSUPRI, which contributed $207.854 million, while ARIKAYCE generated $98.110 million.
Net loss narrowed to $163.563 million from $256.583 million, reflecting higher sales but continued heavy investment in research, development, and commercialization. Operating expenses reached $459.284 million, including $209.485 million for research and development and $247.259 million for selling, general and administrative activities.
Insmed ended the quarter with $582.188 million in cash and cash equivalents and $641.326 million in marketable securities, supporting ongoing losses and pipeline spending. Total assets were $2.076 billion against total liabilities of $1.371 billion, including $542.215 million of long-term debt and $162.137 million related to a royalty financing agreement.
Insmed Inc Chair and CEO William Lewis reported a series of routine equity transactions in the company’s common stock. On May 4, 2026, he sold 10,699 shares in multiple open-market trades at weighted average prices ranging from about $134 to $139.60 per share, executed under a Rule 10b5-1 trading plan adopted on September 4, 2025.
On the same date, he exercised stock options to acquire a total of 10,699 shares of common stock at exercise prices of $17.16 and $30.46 per share. The filing also reflects an indirect holding of 233,924 shares held by trust, indicating Lewis continues to maintain a significant ownership position in Insmed alongside these transactions.
FMR LLC reports beneficial ownership of 13,145,166.52 shares of INSMED INC common stock, representing 6.1% of the class as of 03/31/2026. The filing (Schedule 13G) lists sole dispositive power for 13,145,166.52 shares and zero shared voting/dispositive power. The CUSIP is 457669307 and the filing identifies Abigail P. Johnson in a related capacity.
INSM submitted a Form 144 reporting proposed sales of Common stock. The filing, dated 05/04/2026, lists multiple sale entries by William Lewis with transaction dates from 02/03/2026 through 04/16/2026. The entries are recorded under "Stock Plan Activity" and identify Common shares to be sold on NASDAQ.
Insmed Inc reported a Schedule 13G filing showing Vanguard Capital Management beneficially owned 11,514,893 shares of Common Stock, representing 5.34% of the class as of 03/31/2026. The filer reports 1,872,762 shares of sole voting power and sole dispositive power over 11,514,893 shares.
INSMED Inc Chair and CEO William Lewis exercised stock options and sold shares in INSMED Inc. On April 16, 2026, he exercised options for 10,699 shares of Common Stock at exercise prices of $30.46 and $17.16 per share.
That same day he sold a total of 10,699 shares of Common Stock in open-market transactions at weighted average prices between $142.39 and $146.02 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions he directly held 301,185 shares, with an additional 233,924 shares held indirectly by a trust.
INSM reports proposed sales of Common stock on a Form 144, listing multiple sale dates and share counts attributable to William Lewis under stock plan activity. The filing lists transactions dated 04/06/2026, 03/19/2026, 03/05/2026, and earlier 2026 dates with corresponding numeric entries.
Insmed Inc Chair and CEO William Lewis reported option exercises and share sales in Insmed common stock. On April 6, 2026, he exercised stock options for a total of 10,699 shares at strike prices of $30.46 and $17.16 per share, then sold 10,699 shares in open-market transactions at weighted average prices around $161.73, $163.23, and $164.01. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, he directly owned about 301,185 shares of common stock, with an additional 233,924 shares held indirectly through the Katie Procter Dynasty Trust.
Insmed Incorporated reported that its Phase 2b CEDAR trial of brensocatib in moderate to severe hidradenitis suppurativa did not meet its primary or secondary efficacy endpoints, and the company will discontinue development of brensocatib for HS.
The randomized, double-blind, placebo-controlled study enrolled 214 patients across 72 global sites. At Week 16, abscess and inflammatory nodule counts fell 45.5% and 40.3% in the 10 mg and 40 mg brensocatib arms, compared with a 57.1% reduction on placebo, indicating no efficacy advantage. Safety was consistent with prior studies, with similar rates of treatment-emergent adverse events and no new safety signals at either dose.
INSM filed a Form 144 reporting proposed sales of Common stock and recent stock-plan related activity. The cover lists a proposed sale date of 04/06/2026 on NASDAQ and identifies William Lewis as the reporting seller. The filing itemizes multiple reported sales by William Lewis dated between 01/06/2026 and 03/19/2026, each with the disclosed reported share counts.